Advances in understanding sepsis

European Journal of Anaesthesiology

Volumn 25, Issue SUPPL. 42, 2008, Pages 146-153

  Shimaoka, M ^a   Park, E J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Apoptosis; Cholinergic fibres; Coagulation; Immunosupression; Inflammation; Sepsis

Indexed keywords

ACTIVATED PROTEIN C; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; CHOLINERGIC RECEPTOR STIMULATING AGENT; PROTEIN C;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; BLOOD CLOTTING; CHOLINERGIC SYSTEM; CYTOKINE PRODUCTION; DENDRITIC CELL; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INNATE IMMUNITY; LYMPHOCYTE ACTIVATION; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; VAGUS NERVE; ANIMAL; BIOLOGICAL MODEL; CENTRAL NERVOUS SYSTEM; IMMUNE SYSTEM; INFLAMMATION; INTENSIVE CARE; LYMPHOCYTE; METABOLISM; PATHOLOGY;

ANIMALS; APOPTOSIS; CENTRAL NERVOUS SYSTEM; CHOLINERGIC AGONISTS; HUMANS; IMMUNE SYSTEM; IMMUNITY, NATURAL; INFLAMMATION; INTENSIVE CARE; LYMPHOCYTES; MODELS, BIOLOGICAL; PROTEIN C; SEPSIS; TUMOR NECROSIS FACTOR-ALPHA; VAGUS NERVE;

EID: 43149112066     PISSN: 02650215     EISSN: 13652346     Source Type: Journal    
DOI: 10.1017/S0265021507003389     Document Type: Review

References (61)

1. Russell JA. Management of sepsis. N Engl J Med 2006; 355: 1699-1713.
2. Rice TW, Bernard GR. Therapeutic intervention and targets for sepsis. Annu Rev Med 2005; 56: 225-248.
3. Bone RC. Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann Intern Med 1996; 125: 680-687.
4. Kox WJ, Volk T, Kox SN, Volk HD. Immunomodulatory therapies in sepsis. Intensive Care Med 2000; 26: S124-S128.
5. Lakhani SA, Bogue CW. Toll-like receptor signaling in sepsis. Curr Opin Pediatr 2003; 15: 278-282.
6. Reinhart K, Karzai W. Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit Care Med 2001; 29: S121-S125.
7. Panacek EA, Marshall JC, Albertson TE et al. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab′)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 2004; 32: 2173-2182.
8. Fisher Jr CJ, Agosti JM, Opal SM et al. Treatment of septic shock with the tumor necrosis factor receptor : Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996; 334: 1697-1702.
9. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005; 128: 862-869.
10. Genovese MC, Becker JC, Schiff M et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005; 353: 1114-1123.
11. Zeerleder S, Hack CE, Wuillemin WA. Disseminated intravascular coagulation in sepsis. Chest 2005; 128: 2864-2875.
12. Slofstra SH, ten Cate H, Spek CA. Signal transduction induced by activated protein C: no role in protection against sepsis? Trends Mol Med 2006; 12: 374-381.
13. Marlar RA, Mastovich S. Hereditary protein C deficiency: a review of the genetics, clinical presentation, diagnosis and treatment. Blood Coagul Fibrinolysis 1990; 1: 319-330.
14. Dahlback B, Villoutreix BO. Regulation of blood coagulation by the protein C anticoagulant pathway: novel insights into structure-function relationships and molecular recognition. Arterioscler Thromb Vasc Biol 2005; 25: 1311-1320.
15. Yuksel M, Okajima K, Uchiba M, Horiuchi S, Okabe H. Activated protein C inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappa B and activator protein-1 in human monocytes. Thromb Haemost 2002; 88: 267-273.
16. Zeng W, Matter WF, Yan SB, Um SL, Vlahos CJ, Liu L. Effect of drotrecogin alfa (activated) on human endothelial cell permeability and Rho kinase signaling. Crit Care Med 2004; 32: S302-S308.
17. Fourrier F, Chopin C, Goudemand J et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992; 101: 816-823.
18. Boehme MW, Deng Y, Raeth U et al. Release of thrombomodulin from endothelial cells by concerted action of TNF-alpha and neutrophils: in vivo and in vitro studies. Immunology 1996; 87: 134-140.
19. Boldt J, Papsdorf M, Rothe A, Kumle B, Piper S. Changes of the hemostatic network in critically ill patients - is there a difference between sepsis, trauma and neurosurgery patients? Crit Care Med 2000; 28: 445-450.
20. Taylor Jr FB, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of E. coli infusion in the baboon. J Clin Invest 1987; 79: 918-925.
21. Bernard GR, Vincent JL, Laterre PF et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
22. Abraham E, Laterre PF, Garg R et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005; 353: 1332-1341.
23. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 2005; 5: 331-342.
24. Wang H, Bloom O, Zhang M et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285: 248-251.
25. Yu M, Wang H, Ding A et al. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 2006; 26: 174-179.
26. Fiuza C, Bustin M, Talwar S et al. Inflammationpromoting activity of HMGB1 on human microvascular endothelial cells. Blood 2003; 101: 2652-2660.
27. Raman KG, Sappington PL, Yang R et al. The role of RAGE in the pathogenesis of intestinal barrier dysfunction after hemorrhagic shock. Am J Physiol Gastrointest Liver Physiol 2006; 291: G556-G565.
28. Yang H, Ochani M, Li J et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 2004; 101: 296-301.
29. Ulloa L, Ochani M, Yang H et al. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci USA 2002; 99: 12351-12356.
30. Aneja R, Fink MP. Promising therapeutic agents for sepsis. Trends Microbiol 2006.
31. Scumpia PO, Moldawer LL. Biology of interleukin-10 and its regulatory roles in sepsis syndromes. Crit Care Med 2005; 33: S468-S471.
32. Hotchkiss RS, Nicholson DW. Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 2006; 6: 813-822.
33. Wesche DE, Lomas-Neira JL, Perl M, Chung CS, Ayala A. Leukocyte apoptosis and its significance in sepsis and shock. J Leukoc Biol 2005; 78: 325-337.
34. Adrain C, Brumatti G, Martin SJ. Apoptosomes: protease activation platforms to die from. Trends Biochem Sci 2006; 31: 243-247.
35. Hotchkiss RS, Osmon SB, Chang KC, Wagner TH, Coopersmith CM, Karl IE. Accelerated lymphocyte death in sepsis occurs by both the death receptor and mitochondrial pathways. J Immunol 2005; 174: 5110-5118.
36. Hotchkiss RS, Swanson PE, Knudson CM et al. Overexpression of Bcl-2 in transgenic mice decreases apoptosis and improves survival in sepsis. J Immunol 1999; 162: 4148-4156.
37. Hotchkiss RS, Chang KC, Grayson MH et al. Adoptive transfer of apoptotic splenocytes worsens survival, whereas adoptive transfer of necrotic splenocytes improves survival in sepsis. Proc Natl Acad Sci USA 2003; 100: 6724-6729.
38. Henson PM, Bratton DL, Fadok VA. The phosphatidylserine receptor: a crucial molecular switch? Nat Rev Mol Cell Biol 2001; 2: 627-633.
39. Bannerman DD, Goldblum SE. Mechanisms of bacterial lipopolysaccharide- induced endothelial apoptosis. Am J Physiol Lung Cell Mol Physiol 2003; 284: L899-L914.
40. Husain KD, Coopersmith CM. Role of intestinal epithelial apoptosis in survival. Curr Opin Crit Care 2003; 9: 159-163.
41. Chung CS, Xu YX, Wang W, Chaudry IH, Ayala A. Is Fas ligand or endotoxin responsible for mucosal lymphocyte apoptosis in sepsis? Arch Surg 1998; 133: 1213-1220.
42. Bommhardt U, Chang KC, Swanson PE et al. Akt decreases lymphocyte apoptosis and improves survival in sepsis. J Immunol 2004; 172: 7583-7591.
43. Hotchkiss RS, Tinsley KW, Swanson PE et al. Prevention of lymphocyte cell death in sepsis improves survival in mice. Proc Natl Acad Sci USA 1999; 96: 14541-14546.
44. Hotchkiss RS, Chang KC, Swanson PE et al. Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nat Immunol 2000; 1: 496-501.
45. Wesche-Soldato DE, Chung CS, Lomas-Neira J, Doughty LA, Gregory SH, Ayala A. In vivodelivery of caspase-8 or Fas siRNA improves the survival of septic mice. Blood 2005; 106: 2295-2301.
46. Cauwels A, Janssen B, Waeytens A, Cuvelier C, Brouckaert P. Caspase inhibition causes hyperacute tumor necrosis factor-induced shock via oxidative stress and phospholipase A2. Nat Immunol 2003; 4: 387-393.
47. Stephenson DA, Toltl LJ, Beaudin S, Liaw PC. Modulation of monocyte function by activated protein C, a natural anticoagulant. J Immunol 2006; 177: 2115-2122.
48. Cheng T, Liu D, Griffin JH et al. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med 2003; 9: 338-342.
49. Andersson J. The inflammatory reflex - introduction. J Intern Med 2005; 257: 122-125.
50. Czura CJ, Tracey KJ. Autonomic neural regulation of immunity. J Intern Med 2005; 257: 156-166.
51. Ulloa L. The vagus nerve and the nicotinic antiinflammatory pathway. Nat Rev Drug Discov 2005; 4: 673-684.
52. Banks WA, Farr SA, Morley JE. Entry of blood-borne cytokines into the central nervous system: effects on cognitive processes. Neuroimmunomodulation 2002; 10: 319-327.
53. Maier SF, Goehler LE, Fleshner M, Watkins LR. The role of the vagus nerve in cytokine-to-brain communication. Ann NY Acad Sci 1998; 840: 289-300.
54. Borovikova LV, Ivanova S, Zhang M et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000; 405: 458-462.
55. Wang H, Yu M, Ochani M et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003; 421: 384-388.
56. Wang H, Liao H, Ochani M et al. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 2004; 10: 1216-1221.
57. Saeed RW, Varma S, Peng-Nemeroff T et al. Cholinergic stimulation blocks endothelial cell activation and leukocyte recruitment during inflammation. J Exp Med 2005; 201: 1113-1123.
58. Borovikova LV, Ivanova S, Nardi D et al. Role of vagus nerve signaling in CNI-1493-mediated suppression of acute inflammation. Auton Neurosci 2000; 85: 141-147.
59. Huston JM, Ochani M, Rosas-Ballina M et al. Splenectomy inactivates the cholinergic antiinflammatory pathway during lethal endotoxemia and polymicrobial sepsis. J Exp Med 2006; 203: 1623-1628.
60. Rivers E, Nguyen B, Havstad S et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345: 1368-1377.
61. Otero RM, Nguyen HB, Huang DT et al. Early goal-directed therapy in severe sepsis and septic shock revisited: concepts, controversies, and contemporary findings. Chest 2006; 130: 1579-1595.